CytomX Therapeutics (CTMX) is expected to report fourth-quarter and full-year 2023 results soon. In the last reported quarter, the company beat earnings expectations by 123.53%.Factors to NoteCytomX does not have any marketed product. Investor focus on the fourth-quarter 2023 earnings call will be on updates regarding key cancer immunotherapeutic candidates, CX-904 and BMS-986288.CX-904 is an EGFR-CD3 T-cell engager, developed in partnership with Amgen (AMGN) , while BMS-986288 is a non-fucosylated CTLA-4 t ...

- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 - - Initiation of CX-801 Phase 1 clinical study in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma also anticipated in 1H 2024 - SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it has received clearance from ...

Financial Data and Key Metrics Changes - For Q3 2023, revenue was $26.4 million, compared to $11.1 million for the same period in 2022, indicating a significant increase [45] - Operating expenses for Q3 2023 were $23.3 million, with R&D expenses decreasing by $14 million to $16.4 million compared to the same period in 2022 [45] - Overall cash burn in Q3 was $16.8 million, down from $33.9 million in the equivalent period of 2022, reflecting improved capital allocation and cash management [18] Business Line Data and Key Metrics Changes - CX-904 is advancing through Phase 1 with initial data expected in the first half of 2024, focusing on EGFR positive tumors [5][46] - CX-2051 is on track for IND filing by the end of 2023, with Phase 1 initiation planned for 2024, particularly targeting colorectal cancer [5][46] - CX-801, a masked version of Interferon Alpha-2b, is also on track for IND filing by the end of 2023, with clinical initiation expected in 2024 [15][46] Market Data and Key Metrics Changes - The company has partnerships with major players like Moderna, Regeneron, Astellas, Amgen, and BMS, which enhance its platform and provide non-dilutive financing [6][42] - The company has over 15 active R&D programs, with significant potential for milestone payments from partnerships [42] Company Strategy and Development Direction - The company is focused on the discovery and development of novel cancer medicines using its Probody Therapeutic platform, aiming to localize potent biologics into diseased tissue [4] - The strategy includes a disciplined approach to capital allocation and maintaining a strong financial position amid a challenging biotech environment [18][16] - The pipeline includes T-cell engagers, ADCs, and cytokines, with a focus on delivering value-creating milestones in 2024 and 2025 [20] Management's Comments on Operating Environment and Future Outlook - Management highlighted the strong fundamentals of the company and its positioning for future growth despite external challenges in the biotech sector [4] - The company anticipates multiple inflection points over the next 12 to 18 months as it continues its work in oncology R&D [21] Other Important Information - The company expects its current cash resources to fund operations into the second half of 2025, without assuming additional milestones from partnerships [18] - Management emphasized the importance of partnerships in expanding the reach of their technology and providing financial support [33] Q&A Session Summary Question: Expectations for upcoming data in the first half of next year - Management indicated that initial data from Phase 1a for CX-904 is expected in the first half of 2024, with decisions on expansion cohorts to follow [23][50] Question: Specific tumor types of interest for CX-801 - Management noted that CX-801 has shown clinical activity in several tumor types, including melanoma and renal cancers, and will focus on immune-competent tumors [54] Question: Update on collaborations with Astellas and Regeneron - Management expressed excitement about the partnerships, highlighting ongoing work in bispecific immunotherapies and the potential for significant future developments [62]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commis ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2023 Results Conference Call August 8, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer Conference Call Participants Roger Song - Jefferies Priyanka Grover - JP Morgan Dipesh Patel - H.C. Wainwright Operator Good day, and welcome to the CytomX Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. After the sp ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 Commission File Number 001-37587 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.00001 par value per share CTMX Nasdaq Global Select Market Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of th ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Chris Ogden - SVP, Finance & Accounting Sean McCarthy - CEO and Chairman Conference Call Participants Mitchell Kapoor - H.C. Wainwright Roger Song - Jefferies Malcolm Kuno - JP Morgan Operator Good afternoon, everyone. Thank you for standing by. Welcome to the CytomX Therapeutics First Quarter 2023 Financial Results Call. Please be advised that today's call is being recorded. I would now like ...

The FDA's policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. We also cannot pred ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2022 Earnings Conference Call March 27, 2023 5:00 PM ET Company Participants Chris Ogden - SVP of Finance and Accounting Sean McCarthy - CEO and Chairman Conference Call Participants Roger Song - Jefferies Mara Goldstein - Mizuho Group Peter Lawson - Barclays Mitchell Kapoor - H.C. Wainwright Anupam Rama - JPMorgan Etzer Darout - BMO Capital Markets Operator Good day and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2022 Financial Res ...

Within 60 days following submission of the application, the FDA reviews a BLA to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is acce ...